Emcure Pharmaceuticals IPO
Emcure Pharmaceuticals Ltd.
Emcure Pharmaceuticals IPO Details
| Bidding Dates | Min. Investment | Lot Size | Price Range |
|---|---|---|---|
| To be announced | -- | -- | -- |
| Issue Size | IPO Doc |
|---|---|
| 0 | DRHP PDF |
About Emcure Pharmaceuticals
Emcure Pharmaceutical is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing, and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. It is the largest pharmaceutical company in India in the gynecology, blood-related, and HIV antivirals therapeutic areas, based on sales in India in the Financial Year 2021. Emcure is an R&D-driven company with a differentiated product portfolio that includes orals, injectables, and biologics, as well as an mRNA platform through which it is currently developing a COVID-19 vaccine that has enabled it to reach a range of target markets across over 70 countries. ;
Parent Organisation
Emcure Pharmaceuticals Ltd.
Founded
1981
Managing Director
Satish Mehta
Strengths & Risks
- Emcure’s core strength lies in its ability to research, develop, and manufacture in-house niche pharmaceutical products for high-growth therapeutic areas, for which there is limited competition and high barriers to entry.
- Well-positioned to leverage leading position in the domestic market.
- Large, diversified, and fast-growing product portfolio in the international markets.
- Strong capabilities and a proven track record in building brands.
- Extensive and diversified manufacturing capacity.
- De-risked business model with a diversified income base.
- Highly qualified, experienced, and entrepreneurial management team and board.
- Business model focused on the compliance of Environmental, Social, and Governance (ESG) norms.
- Any manufacturing or quality control problems.
- Any delay, interruption, or reduction in the supply or transportation of its raw materials or finished products.
- Slowdown or shutdown in its manufacturing or R&D operations.
- Adverse order, including the imposition of penalties, in an investigation instituted by the Competition Commission of India against Emcure and others, alleging cartelization in the marketing of an oral anti-diabetes formulation.
- Failure to obtain, maintain or renew its statutory and regulatory licenses, permits, and approvals required to operate its business.
- Inability to accurately forecast demand for its products and manage its inventory.
- Pricing pressure from customers may affect its ability to maintain or increase its product prices.
- Significant proportion of its revenue is derived from its sale of products in certain therapeutic areas in India, such as the gynecology and cardiovascular therapeutic areas.
Financials
*All values are in Rs. Cr
No Graph Data To Display
Application details
| Apply as | Price band | Apply upto |
|---|
For Emcure Pharmaceuticals IPO, eligible investors can apply as
MOST POPULAR ON GROWWVERSION - 4.9.4
STOCK MARKET INDICES: S&P BSE SENSEX | S&P BSE 100 | NIFTY 100 | NIFTY 50 | NIFTY MIDCAP 100 | NIFTY BANK | NIFTY NEXT 50
POPULAR MUTUAL FUNDS: QUANT SMALL CAP FUND | ICICI PRUDENTIAL COMMODITIES FUND | NIPPON INDIA SMALL CAP FUND | PARAG PARIKH FLEXI CAP FUND | GROWW NIFTY TOTAL MARKET INDEX FUND | SBI SMALL MIDCAP FUND | TATA DIGITAL INDIA FUND | AXIS SMALL CAP FUND | ICICI PRUDENTIAL TECHNOLOGY FUND | HDFC INDEX FUND SENSEX PLAN | HDFC SMALL CAP FUND | AXIS EQUITY FUND | CANARA ROBECO SMALL CAP FUND | TATA SMALL CAP FUND | UTI NIFTY FUND
MUTUAL FUNDS COMPANIES: GROWWMF | SBI | AXIS | HDFC | UTI | NIPPON INDIA | ICICI PRUDENTIAL | TATA | KOTAK | DSP | CANARA ROBECO | SUNDARAM | MIRAE ASSET | IDFC | FRANKLIN TEMPLETON | PPFAS | MOTILAL OSWAL | INVESCO | EDELWEISS | ADITYA BIRLA SUN LIFE | LIC | HSBC | NAVI | QUANTUM | UNION | ITI | MAHINDRA MANULIFE | 360 ONE | BOI | TAURUS | JM FINANCIAL | PGIM | SHRIRAM | BARODA BNP PARIBAS | QUANT | WHITEOAK CAPITAL | TRUST | SAMCO | NJ